This phase II clinical trial studies how well cabozantinib works in treating patients with
kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.
I. To assess the objective response rate (complete and partial responses), following the
administration of cabozantinib for 12 weeks in patients with locally advanced biopsy-proven
non-metastatic clear cell renal cell carcinoma (ccRCC) prior to undergoing surgery.
I. To assess the safety, and tolerability of neoadjuvant cabozantinib.
II. To determine the clinical outcome (disease-free survival [DFS], overall survival [OS]) of
patients with non-metastatic ccRCC who treated with neoadjuvant cabozantinib.
III. To evaluate the surgery related outcomes.
IV. To evaluate correlative studies, including biomarkers, quality of life, and
frailty/sarcopenia assessment of patients with non-metastatic ccRCC who treated with
Patients receive cabozantinib orally (PO) once daily (QD) for 12 weeks in the absence of
disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
Malignant neoplasm of kidney,
Renal Cell Carcinoma,
Stage III Renal Cell Cancer AJCC v8,
Renal Cell Cancer,
clear cell renal cell carcinoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.